Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes
Ended Project Grant Awarded Last action
- Award ID
- R44CA233157
- Recipient
-
Symberix, Inc. UEI HN72U2V5AKN7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,287,050
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $999,480 | |
| Amendment | $0 | |
| Amendment | $987,570 | |
| Original award | $300,000 |
Quick answers
Who received award R44CA233157?
R44CA233157 was awarded to Symberix, Inc. by National Cancer Institute (National Institutes of Health) on August 20, 2018.
How much is award R44CA233157 worth?
$2,287,050 has been obligated on R44CA233157.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award